In a 39-person randomized pilot, people on the support programs regained about 3.6% of body weight in four months, versus roughly 11% with usual care.
Recap by typeshit. Full story at News-Medical.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Lilly says it has reported over 14,000 listings and referred 200+ sellers to regulators. One analyst puts the illicit price near $200 a month.
Lilly is widening its legal push against the black market for its experimental obesity shot, which still has no approval.
Loading…